O. Vit

发表

Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).

M. Sanak, J. Ficker, N. Seersholm, 2017, The Lancet. Respiratory medicine.

Quantitative disease progression model of α‐1 proteinase inhibitor therapy on computed tomography lung density in patients with α‐1 antitrypsin deficiency

N. McElvaney, J. Edelman, R. Sandhaus, 2017, British journal of clinical pharmacology.

Safety of biweekly α1-antitrypsin treatment in the RAPID programme

T. Greulich, C. Vogelmeier, N. McElvaney, 2018, European Respiratory Journal.

Safety of bi-weekly infusion of A1-PI augmentation therapy in RAPID

N. Seersholm, N. McElvaney, J. Edelman, 2015 .

Alpha-1 antitrypsin (A1-PI) treatment slows emphysema progression independent of baseline FEV1

J. Ficker, A. Turner, N. McElvaney, 2017 .

Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews

T. Greulich, M. Miravitlles, Sheetal Sharma, 2022, European Respiratory Review.

The effect of exacerbations on lung density in α1-antitrypsin deficiency

C. Strange, K. Chapman, M. Marin-Galiano, 2022, ERJ Open Research.

The effect of exacerbations on lung density in relation to patient characteristics in the RAPID-RCT trial of alpha-1 antitrypsin therapy

C. Vogelmeier, C. Strange, M. Marin-Galiano, 2021, Imaging.

Increased proportion of slow decliners in patients with alpha-1 protease inhibitor (A1-PI) deficiency following treatment with A1-PI

N. Seersholm, K. Chapman, M. Wencker, 2016 .

Population pharmacokinetics of A1-PI in patients with Alpha-1 antitrypsin deficiency

N. Seersholm, J. Edelman, R. Sandhaus, 2015 .